Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.